HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.

July 10, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $6 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a $6 price target by HC Wainwright & Co. indicates their positive outlook on Clearside Biomedical, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100